SCIENTURE (SCNX, Financial) HOLDINGS has decided to end its Equity Line of Credit as of May 22, 2025. Following this decision, the company submitted a post-effective amendment on June 16, 2025. This amendment relates to the Registration Statement on Form S-1, initially filed with the SEC on December 3, 2025, and activated on February 14, 2025. The amendment effectively deregisters 310,488 shares of common stock that remained unsold under the original registration statement.
This financial maneuver aligns with the company's strategy as it gears up to introduce its first FDA-approved product, Arbli. This product is notable for being the only ready-to-use oral liquid losartan available in the U.S. It is slated to hit the market in the third quarter of 2025. Arbli is designed for use in treating hypertension in individuals over six years old, reducing stroke risk in those with hypertension and left ventricular hypertrophy, and addressing diabetic nephropathy in select type 2 diabetes patients.
